(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

BRRT

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

BRRT

ST13

US500000079340796

Classe

5, 42, 44

Pedido

79340796

Registro

7159645

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

33

Atualização mais recente

02/04/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 42, 44

Data de depósito

25/02/2022

Data de registro

12/09/2023

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

12/09/2023

Última transação

02/04/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

GB

Examinador

LEASER, ANDREW

Unidade examinadora

M80

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

Bicycletx Limited

Representantes

Christina M. Licursi Wolf, Greenfield & Sacks, P.C.

Classificação técnica

Classes Nice

Classe 5Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceuticalsfor use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor use in the treatment and prevention of metabolic diseaseurology and renal diseasein the cardiovascular fieldin the field of hematologyfor use in the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imagingclinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease

Classe 42

Scientific and technological services and research and design relating theretoscientific researchnew product design servicesnew study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific researchconducting clinical trials for others; medical and scientific researchconducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid

Classe 44

Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumoursfor the treatment and prevention of metabolic diseaseurology and renal diseasecardiovascular diseasesfor the treatment and prevention of disease in the field of hematologyfor the treatment and prevention of respiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticalsmedical and pharmaceutical consultation and providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; informationconsultancy and advisory services relating to the aforesaid

Publicações

Histórico de despachos e eventos da marca no USPTO.

33 publicações encontradas

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

26/03/2025

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

26/03/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

26/03/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

26/03/2025

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

26/03/2025

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

26/03/2025

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

08/01/2024

FICS

FINAL DISPOSITION NOTICE SENT TO IB

14/12/2023

FIMP

FINAL DISPOSITION PROCESSED

14/12/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

12/12/2023

NREP

NEW REPRESENTATIVE AT IB RECEIVED

01/12/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

12/09/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

12/09/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

27/06/2023

PUBO

PUBLISHED FOR OPPOSITION

27/06/2023

GPNX

NOTIFICATION PROCESSED BY IB

26/06/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/06/2023

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

07/06/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/06/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

22/05/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

21/04/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

20/04/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

20/04/2023

RFNT

REFUSAL PROCESSED BY IB

21/11/2022

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

28/10/2022

RFRR

REFUSAL PROCESSED BY MPU

28/10/2022

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

24/09/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

11/09/2022

CNRT

NON-FINAL ACTION WRITTEN

10/09/2022

DOCK

ASSIGNED TO EXAMINER

09/09/2022

MAFR

APPLICATION FILING RECEIPT MAILED

24/05/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

20/05/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

19/05/2022

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace BRRT ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.